ZALTRAP® approved in the EU for metastatic colorectal cancer

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the European Commission (EC) granted marketing authorisation in the European Union for ZALTRAP® (aflibercept) 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news